PCV42 ANTICOAGULATION CONTROL IN DIFFERENT SETTINGS OF CARE: PERCEPTION, DIRECT NON-HEALTH CARE COSTS AND PRODUCTIVITY LOSSES AMONGST PATIENTS WITH ATRIAL FIBRILLATION IN AN ITALIAN REGION  by Aguzzi, G et al.
is observed in 31%, and 8% are with three medicines. Using the
“decision tree” model the monthly cost of mono therapy is 9.71
BGL, for di therapy is 17.77 BGL and three therapy is 25.24 BGL
(exchange rate 1.95 BGL = 1 EURO). The total yearly cost of
outpatient therapy accounts for approximately 242 million BGL
with 65% patients’ co-payment. Sensitivity analysis shows that
the cost of the therapy is inﬂuenced more on changes in the price
of medicines than on therapy complexity. CONCLUSION: The
hypertension is an expensive disease with heavy burden of
co-payment for the Bulgarian patients.
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OBJECTIVES: Using retrospective cost analysis was to estimate
direct in-patient costs and length-of-stay (LOS) in hospital for
acute heart failure (AHF) with one-year follow-up. METHODS:
Patients were hospitalized with acute decompensation (ADHF)
or new-onset of AHF in the Faculty Hospital Brno from January
till December 2005. Burden incurred is divided to standard car-
diology unit (SCU) and intensive care unit (ICU). In-patient care
costs include ﬂat rate of admission, stay and medicinal proce-
dures. The pharmaceuticals are included in daily in-patient rate;
angiography, revascularisations and antiarrhytmics are calcu-
lated separately. The subsequent hospitalizations were followed
for one year. RESULTS: In total, 734 patients (57% male, mean
age 71.7 years) with AHF were analysed. New-onset of AHF
(58.6%) was more common than ADHF; according to the clini-
cal classiﬁcation AHF with mild signs and symptoms prevailed
(46%). The overall direct hospital cost of all patients within
ﬁrst hospitalization was €2.4 million, LOS 8.3 days and mean
in-patient cost was €3295 (including all interventions). Mean
LOS in the SCU was 8.3 days with one-day cost of €55;
mean LOS in the ICU was 3.4 days with one-day cost of €618.
Cardiogenic shock was associated with highest hospitalization
costs (€4156). Total cost of cardiac cathetrisations and revascu-
larisations (50% patients) was €952,247; cost of antiarrhytmic
interventions (PM and ICD; 6.9% patients) was €529216. Mor-
tality during ﬁrst hospitalization was 14.6%. Most patients were
hospitalized due to AHF within 1–3 months after ﬁrst admission
without relation between hospitalization rates. CONCLUSION:
AHF hospitalization is a signiﬁcant source of health care expen-
ditures and has become more frequent as the population ages and
medical care improves survival after acute coronary syndromes.
AHF is associated with poor prognosis and high costs during
hospital admission; the predominant contributors of high costs
are revascularisation procedures (40%), stay in the ICU (31%)
and antiarrhytmic interventions (22%).
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OBJECTIVES: The purpose of the study was to evaluate the
economic burden directly borne by the patient affected with
Atrial Fibrillation, and the satisfaction associated with monitor-
ing of Oral Anticoagulation Therapy (OAT) in different settings
of care, in an Italian Region (Umbria). METHODS: A prospec-
tive, observational and multi-centre (5 centres: 3 anticoagulation
clinics—ACs—and 2 usual settings of care—USCs) study was
designed. Data were collected through case report forms created
ad hoc. Study perspective was the patient’s, thus the costs sus-
tained by the Italian NHS were excluded, and only direct non-
health care costs (out-of-pocket expenses covered either by the
patient or by caregivers for non-health care related services) and
patient’s and caregiver’s productivity losses were taken into
account. Satisfaction with anticoagulation management was
measured by the speciﬁc Duke Anticoagulation Satisfaction scale
(DASS), together with the generic quality of life SF-36 form, both
administered at day one and at the end of the observation period.
RESULTS: A total of 101 patients in ACs and 51 in USCs were
consecutively enrolled. The number of monitoring performed on
a yearly basis resulted 3.5 tests less (-17%) for ACs compared to
USCs (p-value 0.000), while the total time spent of each control
was 7.1 hours less (-47%) for ACs (p-value 0.000). Direct non-
health care costs and production losses per patients on a yearly
basis amounted to an average of Euro 274.5 without signiﬁcant
differences amongst ACs and USCs. DASS in ACs resulted on
average 0.5 points lower than USCs (p-value 0.001): patients in
ACs felt less limitations on physical activities (-0.8 points,
p-value 0.001), hassles (-1.0 points, p-value 0.000) and burdens
(-0.6 points, p-value 0.001). The SF-36 did not detect any sig-
niﬁcant difference in the general health status. CONCLUSION:
ACs appears to be the preferred setting of care for OAT moni-
toring when considering patient’s perspective.
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OBJECTIVES: Global cardiometabolic risk represents the
overall risk of developing type 2 diabetes (T2DM) and/or car-
diovascular disease (including MI and stroke), which is due to a
cluster of modiﬁable risk factors/markers. The objective of our
study is to determine the direct medical costs imposed on the
Insurer in Hungary relation with the treatment of the most
important cardiovascular diseases and T2DM. METHODS:
Individual-level treatment data of 16,880 patients suffering of
Acute myocardial infarction (AMI), angina, stroke, and transient
ischemic attack (TIA) and having primary care at a inpatient
institute were processed by using ﬁnancing database containing
reimbursement data of 2-year outpatient and inpatient cares The
mean costs of cardiovascular disease were divided into sub-costs
of acute treatment and of 6-month follow-up treatment. Cost of
T2DM was calculated using a doctor’s questionnaire assessing
the probability (frequency) of interventions, and treatments
speciﬁed in the current guideline. 2005 price level were used.
RESULTS: The mean acute treatment costs of AMI was €932
(fatal) and €2017 (non-fatal); of angina was €1489; of stroke was
€935 (fatal) and €1056 (non-fatal); of TIA was €781 to the
Insurer. The 6-month follow-up cost in case of 2TDM was €350,
AMI was €2006, angina was €1679, stroke was €3110 and TIA
was €1749. CONCLUSION: According to our calculations, the
main complications of cardiometabolic risk represent signiﬁcant
expenses to the Insurer. The results give opportunity to evaluate
the cost-effectiveness of health technologies used in the manage-
ment of cardiometabolic risks factors.
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